Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: A retrospective cohort study - 18/06/25
Abstract |
Background |
Limited data exist on managing psoriasis and psoriatic arthritis (PsA) in survivors of major adverse cardiovascular events (MACEs).
Objective |
To investigate the risk of recurrent and new-onset MACEs associated with systemic therapies for psoriasis and PsA.
Methods |
A retrospective cohort study using Korean health insurance data (January 2008-October 2021) included patients diagnosed with psoriasis or PsA treated with biologics, nonbiologic systemic therapy, or phototherapy. The primary outcome was MACE (acute myocardial infarction, stroke, cardiac arrest, unstable angina, or heart failure). Multivariable time-dependent Cox regression models were used for risk analysis.
Results |
The study included 183,212 patients, yielding 259,475 treatment episodes. Biologic therapy was associated with a lower risk of new-onset and recurrent MACEs compared to phototherapy (adjusted hazard ratio, 0.454; 95% confidence interval [CI], 0.359-0.574; 0.343, 95% CI, 0.245-0.479, respectively). Nonbiologic systemic therapy showed a lower MACE risk than did phototherapy only in patients with a history of MACE (adjusted hazard ratio, 0.789; 95% CI, 0.658-0.946).
Limitations |
Observational design limits causal inference and may involve residual confounding.
Conclusion |
The study supports the use of biologics in patients with moderate-to-severe psoriasis or PsA, particularly those with a MACE history where treatment options are limited.
Il testo completo di questo articolo è disponibile in PDF.Key words : biologics, cardiovascular, cardiovascular disease, CVD, MACE, major adverse cardiovascular event, psoriasis, psoriatic arthritis, systemic
Abbreviations used : CI, CVD, HIRA, HR, IL, IQR, MACE, PsA, PY, SD, TNF-α
Mappa
| Funding sources: The study was supported by the Dongwha Pharmaceutical Research Fund 2023, with no funder involvement in the study. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Exempted from IRB approval (IRB no. 07-2022-24). |
Vol 93 - N° 1
P. 141-149 - luglio 2025 Ritorno al numero
Articolo precedente
- Tumor-infiltrating lymphocyte scoring improves progression risk prediction in stage II melanoma: A retrospective cohort study
- George Adigbli, Benedict Reed, Bhavika Khera, Mahaveer Sangha, Simran Thadani, Annika B. Wilder-Smith, Milosz Wojtowicz, Mary Pissaridou, Ameer Mustafa, Eleni Ieremia, Olivia Espinosa, Jonathan Dunne, Fadi Issa, Oliver Cassell
- Limitations of the commercially available gene expression test in predicting cutaneous squamous cell carcinoma metastasis and clinical outcomes
- Joel L. Sax, Christopher D. McFarland, Bryan T. Carroll
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?